Blueprint And Ardelyx Join List Of Biotechs Selling Royalties To Raise Funds

Amid Market Doldrums

 
• By Ayisha Sharma
  
Biotech Firms Are Selling Future Royalties Amid The Cash Crunch • Source: Shutterstock

More from Financing

More from Business